Hologic's Strong International Traction to Continue Despite Headwinds

Hologic's international expansion is a core growth strategy, with its GYN Surgical segment demonstrating robust performance, achieving nearly 25% international growth in Q3 FY2025 driven by minimally invasive products and new market uptake. While the Diagnostics segment outside the U.S. is expected to remain under pressure through 2025 due to macroeconomic factors like China's operating landscape and USAID funding cuts, the company anticipates meaningful overall international growth through 2026 and beyond. Hologic forecasts its international business to expand at a 4.7% CAGR between fiscal 2025 and 2027, leveraging significant global opportunities in areas such as 3D mammography and STI testing.

Analysis

Hologic (HOLX) presents a dichotomous international growth narrative, balancing significant headwinds with robust long-term opportunities. The company's Diagnostics segment is expected to face pressure outside the United States through 2025, stemming from a challenging operating environment in China and cuts to USAID funding for its HIV testing business in Africa. Concurrently, tariffs will continue to weigh on margins despite mitigation efforts. In stark contrast, the GYN Surgical segment is demonstrating exceptional strength, with international sales growing nearly 25% in the third quarter of fiscal 2025, driven by strong portfolio momentum and new market reimbursement. This is further supported by consistent double-digit overseas growth from products like NovaSure, even as domestic sales decline. The company's growth outlook is underpinned by a forecasted 4.7% CAGR for its international business between fiscal 2025 and 2027. Key future growth levers include the vast, underdeveloped global markets for 3D mammography, where Hologic holds a dominant 85% share in the U.S., and STI testing. The ongoing global rollout of the Genius digital diagnostics system and record-high utilization of the Panther platform signal strong product adoption. Despite the stock's 18.2% decline over the past year, which mirrors the industry's 18.4% drop, its valuation appears modest. Hologic trades at a forward three-year price-to-sales ratio of 3.57x, below the industry average of 3.96x, and carries a Value Score of B, suggesting a potential dislocation between current price and long-term growth prospects.

Key Decisions for Investors

• Investors should weigh the identified near-term headwinds in the Diagnostics segment, particularly in China and Africa through 2025, against the compelling long-term growth trajectory driven by the GYN Surgical and Mammography divisions.
• Given the stock's 18.2% year-over-year decline and its valuation discount to the industry on a forward price-to-sales basis, value-oriented investors may find the current level an attractive entry point if confident in the international expansion thesis.
• Monitor the quarterly international growth figures for the GYN Surgical segment and global adoption rates of the Panther and Genius platforms as key performance indicators to validate that the growth story is offsetting the anticipated weakness in diagnostics.